Encapsulation of dasatinib in iron-, zinc-, and zirconium-based metal-organic frameworks: A strategy for controlled delivery and cardiotoxicity reduction
Authors:
- Katarina Sokač PogrmilovićKatarina Sokač Pogrmilović
- Kornelia HyjekKHKornelia Hyjek
- Anna Boguszewska-CzubaraABAnna Boguszewska-Czubara
- Anna PajdakAPAnna Pajdak
- Przemysław J. JodłowskiPrzemysław J. Jodłowski
- 12 April 2026
- journal article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 121
Abstract
No abstract availableFunding Information
- Hrvatska Zaklada za Znanost
This publication has 84 references indexed in Scilit:
- Multiscale Profiling of Nanoscale Metal‐Organic Framework Biocompatibility and Immune InteractionsAdvanced Healthcare Materials, 2025
- Synthesis and characterization of MIL-101 (Fe) as efficient catalyst for tetracycline degradation by using NaBH4: Artificial neural network modelingApplied Surface Science Advances, 2023
- Design and Advanced Manufacturing of NU‐1000 Metal–Organic Frameworks with Future Perspectives for Environmental and Renewable Energy ApplicationsSmall, 2023
- Recent advances in porous nanomaterials‐based drug delivery systems for osteoarthritisNano Select, 2023
- Metal–organic frameworks encapsulated with an anticancer compound as drug delivery system: Synthesis, characterization, antioxidant, anticancer, antibacterial, and molecular docking investigationApplied Organometallic Chemistry, 2022
- Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single InjectionCellular and Molecular Bioengineering, 2021
- Using MOF-808 as a Promising Support to Immobilize Ru for Selective Hydrogenation of Levulinic Acid to γ-ValerolactoneCatalysis Letters, 2020
- Clinical Pharmacokinetics and Pharmacodynamics of DasatinibClinical Pharmacokinetics, 2020
- Preparation of Metal–Organic Frameworks UiO-66 for Adsorptive Removal of Methotrexate from Aqueous SolutionJournal of Inorganic and Organometallic Polymers and Materials, 2017
- Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABLCancer Chemotherapy and Pharmacology, 2007